ALTH Insider Trading Activity and SEC Form 4 Filings
ALTH insider trading summary
No open-market insider purchases or sales of Allos Therapeutics Inc (ALTH) have been reported on SEC Form 4 in the past 12 months.
Latest ALTH insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 5, 2012 | Spectrum Pharmaceuticals Inc | 10% Owner | Buy | $238.2M (130,854,840 @ $1.82) |
| Sep 5, 2012 | Sapphire Acquisition Sub, Inc. | 10% Owner | Buy | $238.2M (130,854,840 @ $1.82) |
| Jul 11, 2012 | Michael E Schick | VP, Sales and Marketing | Sell | $1K (697 @ $1.78) |
| Apr 27, 2012 | Bruce K Bennett Jr | VP, Pharmaceutical Operations | Buy | $1K (1,104 @ $1.22) |
| Apr 27, 2012 | Charles Q Morris | Chief Medical Officer | Sell | $14K (7,970 @ $1.81) |
| Mar 1, 2012 | David C Clark | VP, Finance | Sell | $5K (3,385 @ $1.50) |
| Mar 1, 2012 | Michael E Schick | VP, Sales and Marketing | Sell | $6K (3,960 @ $1.48) |
| Mar 1, 2012 | Bruce A Goldsmith | SVP, Corporate Development | Sell | $7K (4,473 @ $1.50) |
| Mar 1, 2012 | Marc H Graboyes | SVP, General Counsel | Sell | $14K (9,635 @ $1.48) |
| Mar 1, 2012 | Paul L Berns | Chief Executive Officer | Sell | $32K (21,532 @ $1.48) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.